Vericiguat 5 mg initiation dose tolerability in chronic heart failure with reduced ejection fraction

Phase 2, open-label trial of vericiguat in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Bayer. Primary endpoints: Treatment tolerability (completion of 2-week 5 mg dose without discontinuation) and Treatment tolerability (completion of 2-week 5 mg dose without moderate to severe symptomatic hypotension). Started May 2024; status: completed.